Recent Updates
Recently added Catalysts
RARE

Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases

Thursday, October 29, 2015 1 min read
Key Takeaway: Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases

Full Press Release Details

Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 29, 2015